Recent advances in managing gastrointestinal stromal tumor.

KIT PDGFRα Constitutive activating mutations inand platelet-derived growth factor receptor α () are heavily involved in the pathobiology of gastrointestinal stromal tumors (GISTs). This disease has served as an effective "proof-of-concept" model for targeting gain-of-function kinase mutations in cancer. This review discusses the current standard of care in terms of pharmacotherapy in the management of localized and metastatic GISTs.